Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Amarin
Deal Size : $175.0 million
Deal Type : Licensing Agreement
Amarin Announces Exclusive License and Supply Agreement with Recordati
Details : Under the licensing agreement, Recordati will be responsible for commercialization of Vazkepa (Icosapent Ethyl) in Europe. It is being indicated to reduce the risk of myocardial infarction, stroke.
Product Name : Vascepa
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
June 24, 2025
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Amarin
Deal Size : $175.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Isturisa (osilodrostat) Expanded Indication for Endogenous Hypercortisolemia
Details : Isturisa (osilodrostat phosphate) is approved for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome.
Product Name : Isturisa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Siltuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 08, 2024
Lead Product(s) : Siltuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sutimlimab
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : Sanofi
Deal Size : $1,075.0 million
Deal Type : Acquisition
Recordati Buys Rights to Rare Immune Disorder Drug from Sanofi for $825M
Details : Recordati will acquire the global rights to Enjaymo (sutimlimab), a biologic and the only approved targeted product for cold agglutinin disease, a rare B-cell lymphoproliferative disorder.
Product Name : Enjaymo
Product Type : Antibody
Upfront Cash : $825.0 million
April 10, 2024
Lead Product(s) : Sutimlimab
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : Sanofi
Deal Size : $1,075.0 million
Deal Type : Acquisition
Lead Product(s) : Pasireotide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Pasireotide in People With Prolactinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : Pasireotide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement, ARS Pharmaceuticals Reacquires commercial rights to neffy (ARS-1) in the European region. Neffy is an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions leading to ...
Product Name : Neffy
Product Type : Hormone
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : ARS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Isturisa (osilodrostat phosphate) is an oral inhibitor of 11β-hydroxylase (CYP11B1), which catalyses the final step of cortisol synthesis in the adrenal glands. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets.
Product Name : Isturisa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ISTURISA (osilodrostat), is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Product Name : Isturisa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Osilodrostat Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : IKF Nordwest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 18, 2021
Lead Product(s) : Dinutuximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : IKF Nordwest
Deal Size : Inapplicable
Deal Type : Inapplicable